Aaron Kelly, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota, has noted: "Any off-label GLP-1 use in children under 12 should be treated as a single-patient investigational protocol with IRB-level documentation and monitoring intensity." No published case series or retrospective cohort study has described semaglutide use in children under 12 as of May 2026
Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy
Common side effects of semaglutide include nausea, vomiting, diarrhea, and constipation
What You Can Do & How We Can Help The Schmidt Firm, PLLC is currently accepting Ozempic induced injury cases in all 50 states
GLP 1 Receptor Agonist Cardiovascular Therapy Market Size, Share, Revenue Report 2026 to 2035 What is GLP 1 Receptor Agonist Cardiovascular Therapy Market